Capricor Therapeutics Inc (NASDAQ:CAPR) Receives $24.67 Consensus Target Price from Analysts

Shares of Capricor Therapeutics Inc (NASDAQ:CAPR - Get Free Report) have been given a consensus rating of "Buy" by the six research firms that are presently covering the firm, MarketBeat reports. Six equities research analysts have rated the stock with a buy rating. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $24.67.

CAPR has been the subject of a number of recent analyst reports. Oppenheimer reaffirmed an "outperform" rating and set a $15.00 price target on shares of Capricor Therapeutics in a research report on Monday, September 23rd. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $8.00 price target on shares of Capricor Therapeutics in a research note on Friday, September 20th. HC Wainwright reissued a "buy" rating and set a $40.00 price objective on shares of Capricor Therapeutics in a research report on Wednesday, October 9th. Maxim Group raised their target price on shares of Capricor Therapeutics from $12.00 to $25.00 and gave the stock a "buy" rating in a research report on Wednesday, September 25th. Finally, Piper Sandler initiated coverage on shares of Capricor Therapeutics in a research report on Monday, October 21st. They set an "overweight" rating and a $35.00 price target on the stock.

Capricor Therapeutics Stock Performance

NASDAQ:CAPR traded down $0.22 during midday trading on Wednesday, reaching $18.23. 1,345,597 shares of the stock traded hands, compared to its average volume of 2,347,247. The stock has a market capitalization of $827.82 million, a P/E ratio of -19.60 and a beta of 4.00. The company has a fifty day moving average of $13.22 and a 200 day moving average of $7.82. Capricor Therapeutics has a 12 month low of $2.68 and a 12 month high of $23.40.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last issued its quarterly earnings data on Wednesday, August 7th. The biotechnology company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.03). The firm had revenue of $3.97 million for the quarter, compared to the consensus estimate of $4.51 million. Capricor Therapeutics had a negative net margin of 102.93% and a negative return on equity of 220.27%. On average, analysts predict that Capricor Therapeutics will post -1.17 EPS for the current fiscal year.

Insider Activity

In other news, major shareholder Shinyaku Co Ltd Nippon bought 2,798,507 shares of the company's stock in a transaction dated Friday, September 20th. The shares were purchased at an average price of $5.36 per share, for a total transaction of $14,999,997.52. Following the completion of the purchase, the insider now owns 7,090,351 shares in the company, valued at approximately $38,004,281.36. This represents a 0.00 % increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 12.00% of the company's stock.

Institutional Investors Weigh In On Capricor Therapeutics

Several large investors have recently bought and sold shares of the business. BNP Paribas Financial Markets purchased a new stake in shares of Capricor Therapeutics during the 1st quarter valued at about $40,000. Main Street Financial Solutions LLC boosted its holdings in Capricor Therapeutics by 37.5% in the second quarter. Main Street Financial Solutions LLC now owns 27,500 shares of the biotechnology company's stock worth $131,000 after purchasing an additional 7,500 shares during the last quarter. SG Americas Securities LLC bought a new stake in Capricor Therapeutics in the 3rd quarter worth approximately $133,000. Rhumbline Advisers bought a new stake in Capricor Therapeutics in the 2nd quarter worth approximately $147,000. Finally, Bank of New York Mellon Corp lifted its holdings in shares of Capricor Therapeutics by 12.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 79,782 shares of the biotechnology company's stock valued at $381,000 after buying an additional 9,040 shares during the period. 21.68% of the stock is currently owned by institutional investors.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.